Search results for "trials"

showing 10 items of 966 documents

Randomized Comparative Trial with Ceftizoxime and Cefotaxime in Urinary Tract Infections

1984

Ceftizoxime, a new, semisynthetic, beta-lactamase-resistant cephalosporin, is not metabolized in man and is excreted almost entirely as the original active compound in the urine. The efficacy and safety of ceftizoxime were assessed in 80 patients with acute and chronic urinary infections, with and without associated pathological conditions, in comparison with cefotaxime. Two dosage schedules, 1 g or 0.5 g every 12 h, i.v. or i.m. for 10 days, were adopted according to the severity of each case and to separate randomization tables for each schedule; causal agents were all sensitive to both drugs in vitro. The overall results were excellent. Safety was excellent in almost all cases. In this t…

NephrologyAdultMalemedicine.medical_specialtyCefotaximeRandomizationAdolescentmedicine.drug_classUrologyUrinary systemCephalosporin030232 urology & nephrologyCefotaximeUrineRandom Allocation03 medical and health sciences0302 clinical medicineInternal medicineCeftizoximemedicineHumansAgedClinical Trials as Topicbusiness.industryCeftizoximeDosing regimenBacterial InfectionsDrug ToleranceGeneral MedicineMiddle AgedComparative trialSurgeryNephrology030220 oncology & carcinogenesisUrinary Tract InfectionsFemaleSafetybusinessmedicine.drugUrologia Journal
researchProduct

Kelfiprim, a new sulpha-trimethoprim combination, versus cotrimoxazole, in the treatment of urinary tract infections: a multicentre, double-blind tri…

1982

A new combination of trimethoprim with a sulphonamide, named Kelfiprim, differs from cotrimoxazole in that: a) the sulpha drug is sulphamethopyrazine instead of sulphamethoxazole; b) the trimethoprim to sulpha ratio is 5:4 instead of 1:5;c) the presence of a long-acting sulphonamide allows the administration of a daily dose of one capsule, following an initial loading dose of two capsules; d) a reduced amount of trimethoprim is given, as compared to cotrimoxazole, without any decrease of efficacy. Kelfiprim [KP] was compared to contrimoxazole [Co] in a multicentre double blind trial. Sixty four patients suffering from acute and chronic infections of the upper and lower urinary tract entered…

NephrologyMalemedicine.medical_specialtySulfamethoxazoleUrologyUrinary systemUrineGastroenterologyLoading doseTrimethoprimDouble blindDouble-Blind MethodInternal medicineSulfanilamidesTrimethoprim Sulfamethoxazole Drug CombinationmedicineHumansClinical Trials as Topicbusiness.industrySulfaleneTrimethoprimSurgeryDrug CombinationsUrinary Tract InfectionsFemalebusinessmedicine.drugUrological research
researchProduct

Gender differences in the neurotoxicity of metals in children

2013

Gender-related differences in susceptibility to chemical exposure to neurotoxicants have not received sufficient attention. Although a significant number of epidemiological studies on the neurodevelopmental effects of metal exposure has been published in the last twenty years, not many of them have considered the possible gender-specific effects of such exposure. This review is focused on studies where the gender differences in pre- and/or postnatal exposure/s to five metals (mercury, lead, manganese, cadmium, and arsenic) and neurodevelopment were evaluated. We conducted a PubMed search in December 2012 and retrieved 20 studies that met the inclusion criteria. A large body of literature on…

Nervous systemMalemedicine.medical_specialtyToxicologyToxicologyChemical exposureEnvironmental healthEpidemiologymedicineHumansChildChildrenClinical Trials as TopicSex Characteristicsbusiness.industryNeurotoxicityEnvironmental ExposureMERCURY EXPOSUREmedicine.diseaseMetalsHeavy metal poisoningSexFemaleNeurotoxicity SyndromesNervous System DiseasesbusinessNeurological disordersToxicology
researchProduct

The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Tri…

2021

This article belongs to the Collection The Biomarkers for the Diagnosis and Prognosis in Cancer.

Neuroblastoma RAS viral oncogene homologOncologyCancer Researchgenetic riskMyeloid neoplasialeukemic cells0302 clinical medicinecytarabineclinical trials and observations:Other subheadings::/diagnosis [Other subheadings]MedicineComplete remissionazacytidineolder adultsRC254-282variantsLeukemiaAzacytidineHazard ratioleukemiaVariantsCytarabineacute:Neoplasms::Neoplasms by Histologic Type::Leukemia::Leukemia Myeloid::Leukemia Myeloid Acute [DISEASES]Neoplasms. Tumors. Oncology. Including cancer and carcinogensMyeloid leukemiaFludarabineLeukemiaOncology030220 oncology & carcinogenesisNGSOlder adultsLeucèmia mieloide aguda - Tractamentmyeloid neoplasiaMyelocyticmedicine.drugmedicine.medical_specialtymyelocyticcomplete remission:Otros calificadores::/diagnóstico [Otros calificadores]Subgroup analysisLeukemic cellsAcutePrognostic factorsArticle:neoplasias::neoplasias por tipo histológico::leucemia::leucemia mieloide::leucemia mieloide aguda [ENFERMEDADES]03 medical and health sciencesInternal medicineGenetic riskbusiness.industryprognostic factors:diagnóstico::pronóstico::resultado del tratamiento [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]Odds ratio:Diagnosis::Prognosis::Treatment Outcome [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT]medicine.diseaseAvaluació de resultats (Assistència sanitària)CytarabinebusinessClinical trials and observations030215 immunology
researchProduct

Controlled education of patients after stroke (ceops)-nurse-led multimodal and long-term interventional program involving a patient''s caregiver to o…

2018

Background Setting up a follow-up secondary prevention program after stroke is difficult due to motor and cognitive impairment, but necessary to prevent recurrence and improve patients’ quality of life. To involve a referent nurse and a caregiver from the patient’s social circle in nurse-led multimodal and long-term management of risk factors after stroke could be an advantage due to their easier access to the patient and family. The aim of this study is to compare the benefit of optimized follow up by nursing personnel from the vascular neurology department including therapeutic follow up, and an interventional program directed to the patient and a caregiving member of their social circle,…

Neurologic ExaminationPatient Care TeamTime FactorsNurseSecondary prevention[SDV]Life Sciences [q-bio]Stroke RehabilitationRecovery of FunctionCombined Modality TherapyNurse's RoleMultimodal intervention;Family caregiver;Nurse;Secondary prevention;Stroke[SDV] Life Sciences [q-bio]StrokeStudy ProtocolDisability EvaluationLeadershipTreatment OutcomeCaregiversPatient Education as TopicMultimodal interventionHumansFranceFamily caregiverRandomized Controlled Trials as Topic
researchProduct

Transarterial chemoembolization and sorafenib in hepatocellular carcinoma

2014

Transarterial chemoembolization (TACE) is considered as the standard therapy for patients with intermediate-stage hepatocellular carcinoma. However, given the high heterogeneity of this population, no common strategy or protocol standardization has been defined yet. In the last few years TACE treatment has been combined with sorafenib systemic therapy, reporting overall positive results both in terms of safety and efficacy. This systematic review presents and critically discusses the evidence available on the use of TACE in combination (concomitant or sequential) with sorafenib, focusing also on clinical trials currently ongoing to better define an optimal therapeutic strategy for this grou…

NiacinamideOncologySorafenibmedicine.medical_specialtyCarcinoma HepatocellularCombination therapyPopulationAntineoplastic AgentsSystemic therapyInternal medicinemedicineHumansPharmacology (medical)Chemoembolization TherapeuticeducationTherapeutic strategyClinical Trials as Topiceducation.field_of_studybusiness.industryPhenylurea CompoundsLiver NeoplasmsSorafenibmedicine.diseaseClinical trialOncologyHepatocellular carcinomaConcomitantRadiologybusinessmedicine.drugExpert Review of Anticancer Therapy
researchProduct

Novel inhibitors in development for hepatocellular carcinoma

2010

The multikinase inhibitor sorafenib was the first agent to demonstrate a survival benefit for patients with locally advanced or metastatic hepatocellular carcinoma (HCC). Although sorafenib represents a landmark in the treatment of HCC and proved molecularly targeted therapy to be effective in this disease, it represents just the first step towards an improvement in systemic therapy. Since then, novel inhibitors have been evaluated in early clinical trials, showing potential activity.This article aims to review novel inhibitors emerging in the field of advanced HCC. An Internet-based search was performed to identify abstracts, clinical trials ( www.clinicaltrials.gov , last accessed 30 Nove…

NiacinamideSorafenibOncologymedicine.medical_specialtyCarcinoma HepatocellularPyridinesmedicine.medical_treatmentMEDLINEAntineoplastic AgentsDiseasePharmacologySystemic therapyTargeted therapyDrug Delivery SystemsInternal medicinemedicineCarcinomaAnimalsHumansPharmacology (medical)PharmacologyClinical Trials as Topicbusiness.industryPhenylurea CompoundsBenzenesulfonatesLiver NeoplasmsDrugs InvestigationalGeneral MedicineSorafenibmedicine.diseasedigestive system diseasesClinical trialDrug DesignHepatocellular carcinomabusinessSignal Transductionmedicine.drugExpert Opinion on Investigational Drugs
researchProduct

Medium-chain triglycerides may improve memory in non-demented older adults: a systematic review of randomized controlled trials

2022

Abstract Background Ketosis has been exploited for its neuroprotective impact and treatment of neurological conditions via ketone production. Exogenous medium-chain triglyceride (MCT) supplementation may induce nutritional ketosis. The aim of this systematic review is to explore the effects of MCTs on memory function in older adults without cognitive impairment. Methods A systematic literature search of PubMed, Cochrane Library, Scopus, and Web of Science was employed from inception until April 2022 for randomized controlled trials (RCTs) in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, investigating the impact of MCT oils on com…

Non-demented1106 Human Movement and Sports Sciences1103 Clinical SciencesKetone BodiesKetosisMedium-chain triglyceridesNutritional ketosisMemoryGeriatricsVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Geriatri: 778HumansCognitive functionGeriatrics and GerontologyOilsTriglyceridesAgedRandomized Controlled Trials as TopicBMC geriatrics
researchProduct

Nonalcoholic steatohepatitis: the therapeutic challenge of a global epidemic.

2011

Nonalcoholic fatty liver (NAFL) and especially its inflammatory variant nonalcoholic steatohepatitis (NASH) have become a major challenge to healthcare systems worldwide because of the increasing prevalence of its major risk factors obesity and type 2 diabetes, which are closely linked to overeating, physical inactivity, and the metabolic syndrome.Between 10 and 20% of patients with NAFL develop NASH, which can progress to cirrhosis, end-stage liver disease, and hepatocellular carcinoma. The overall mortality in these patients is significantly increased because of both cardiovascular and liver-related complications. Sustained weight loss by diet and exercise, which is the most effective the…

Nonalcoholic steatohepatitisDiet ReducingEndocrinology Diabetes and MetabolismAnti-Inflammatory AgentsType 2 diabetesBioinformaticsBile Acids and SaltsNon-alcoholic Fatty Liver DiseaseGeneticsmedicineAnimalsHumansHypoglycemic AgentsObesityEpidemicsMolecular BiologyRandomized Controlled Trials as TopicNutrition and Dieteticsbusiness.industryFatty liverCell Biologymedicine.diseaseObesityFatty LiverHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessHealthcare systemCurrent opinion in lipidology
researchProduct

Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life

2021

Abstract Background and aims Severe asthma is burdened by frequent exacerbations and use of oral corticosteroids (OCS) which worsen patients’ health and increase healthcare spending. Aim of this study was to assess the clinical and economic effect of adding mepolizumab (MEP) for the treatment of these patients. Methods Patients >18 years old, referred to 8 asthma clinics, starting MEP between May 2017 and December 2018, were enrolled and followed-up for 12 months. Information in the 12 months before mepolizumab were collected retrospectively. The evaluation parameters included: OCS use, number of exacerbations/hospitalizations, concomitant therapies, comorbidity, and annual number of workin…

OR Odds RatioPediatricsSevere asthmaExacerbationAnti IL-5; Comorbidities; Mepolizumab; OCS; Pharmacoeconomics; Severe asthmagastroesophageal reflux diseaseSettore MED/10 - MALATTIE DELL'APPARATO RESPIRATORIOICS inhaled corticosteroidRate ratioOCS Oral Corticosteroidslaw.inventionComorbiditiesLAMA long acting muscarinic antagonist0302 clinical medicineRandomized controlled trialfractional nitric oxideInterquartile rangelawlong acting beta 2 agonistOdds RatioImmunology and AllergyRR Rate Ratio030223 otorhinolaryngologyPharmacoeconomicLOS Length of stayLOSIQRLAMAMEP MepolizumabORCISD Standard DeviationMEPPharmacoeconomicsACT Asthma Control TestComorbiditieCI Confidence Intervalsmedicine.druglcsh:Immunologic diseases. AllergyPulmonary and Respiratory Medicinemedicine.medical_specialtyinterquartile rangelong acting muscarinic antagonistImmunologyLABALABA long acting beta 2 agonistComorbidities Mepolizumab OCS Pharmacoeconomics Severe asthma Anti IL-5RRArticleRate Ratiochronic obstructive pulmonary disease03 medical and health sciencesPharmacoeconomicsOCS Oral CorticosteroidAsthma Control TestConfidence IntervalsFeNO fractional nitric oxideRCTs Randomized Controlled TrialmedicineCOPDGERD gastroesophageal reflux diseaseFeNOIQR interquartile rangeMepolizumabSDAsthmaRCTsOral Corticosteroidsbusiness.industryGERDmedicine.diseaseICS inhaled corticosteroidsACTComorbidityRandomized Controlled TrialsCI Confidence IntervalRCTs Randomized Controlled TrialsOCSCOPD chronic obstructive pulmonary disease030228 respiratory systemICSStandard DeviationLength of stayAnti IL-5inhaled corticosteroidslcsh:RC581-607businessMepolizumab
researchProduct